Oxford BioMedica (OXB) Share Forecast & Price Target

Compare

110 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OXB Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Oxford

BioMedica

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OXB Stock 12 Month Forecast

Average Price Target

920.50 p

▲(60.09% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Oxford BioMedica in the last 3 months. The average price target is 920.50 p with a high forecast of 1,170.00 p and a low forecast of 735.00 p. The average price target represents a 60.09% change from the last price of 575.00 p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"290":"290 p","1171":"1,171 p","510.25":"510.3 p","730.5":"730.5 p","950.75":"950.8 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">1.17K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":920.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">920.50 p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":735,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">735.00 p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[290,510.25,730.5,950.75,1171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,645,685.3846153846154,725.7692307692307,766.1538461538462,806.5384615384615,846.9230769230769,887.3076923076924,927.6923076923077,968.0769230769231,1008.4615384615385,1048.8461538461538,1089.2307692307693,1129.6153846153848,{"y":1170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,645,666.1923076923077,687.3846153846154,708.5769230769231,729.7692307692307,750.9615384615385,772.1538461538462,793.3461538461538,814.5384615384615,835.7307692307693,856.9230769230769,878.1153846153846,899.3076923076924,{"y":920.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,645,651.9230769230769,658.8461538461538,665.7692307692307,672.6923076923077,679.6153846153846,686.5384615384615,693.4615384615385,700.3846153846154,707.3076923076923,714.2307692307693,721.1538461538462,728.0769230769231,{"y":735,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":330,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":295,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":464.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":569,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":590,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":657,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":618,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":617,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":830,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":645,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target1,170 p

Average Price Target920.50 p

Lowest Price Target735.00 p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Vane

Jefferies

827 p

Buy

43.83%

Upside

Reiterated

03/23/26

Analysts Are Bullish on Top Healthcare Stocks: Curis (CRIS), Maze Therapeutics, Inc. (MAZE)

James Orsborne

Stifel Nicolaus

950 p

Buy

65.22%

Upside

Reiterated

03/11/26

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT) and Oxford BioMedica (Other OTC: OXBDF)

Charles Weston

RBC Capital

1,170 p

Buy

103.48%

Upside

Initiated

02/27/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Oxford BioMedica (Other OTC: OXBDF), Valneva (NASDAQ: VALN) and Supernus Pharmaceuticals (NASDAQ: SUPN)

Kane Slutzkin

Deutsche Bank

380 p→735 p

Buy

27.83%

Upside

Upgraded

01/06/26

Oxford Biomedica upgraded to Buy from Hold at Deutsche BankOxford Biomedica upgraded to Buy from Hold at Deutsche Bank

Zain Ebrahim

J.P. Morgan

400 p→550 p

Hold

-4.35%

Downside

Reiterated

12/08/25

Oxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorganOxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorgan

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

451 p

Buy

-21.57%

Downside

Reiterated

10/07/25

Oxford BioMedica (OXBDF) Receives a Buy from Canaccord Genuity

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

451 p

Buy

-21.57%

Downside

Reiterated

08/01/25

Peel Hunt Keeps Their Buy Rating on Oxford BioMedica (OXBDF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Vane

Jefferies

827 p

Buy

43.83%

Upside

Reiterated

03/23/26

Analysts Are Bullish on Top Healthcare Stocks: Curis (CRIS), Maze Therapeutics, Inc. (MAZE)

James Orsborne

Stifel Nicolaus

950 p

Buy

65.22%

Upside

Reiterated

03/11/26

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT) and Oxford BioMedica (Other OTC: OXBDF)

Charles Weston

RBC Capital

1,170 p

Buy

103.48%

Upside

Initiated

02/27/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Oxford BioMedica (Other OTC: OXBDF), Valneva (NASDAQ: VALN) and Supernus Pharmaceuticals (NASDAQ: SUPN)

Kane Slutzkin

Deutsche Bank

380 p→735 p

Buy

27.83%

Upside

Upgraded

01/06/26

Oxford Biomedica upgraded to Buy from Hold at Deutsche BankOxford Biomedica upgraded to Buy from Hold at Deutsche Bank

Zain Ebrahim

J.P. Morgan

400 p→550 p

Hold

-4.35%

Downside

Reiterated

12/08/25

Oxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorganOxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorgan

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

451 p

Buy

-21.57%

Downside

Reiterated

10/07/25

Oxford BioMedica (OXBDF) Receives a Buy from Canaccord Genuity

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

451 p

Buy

-21.57%

Downside

Reiterated

08/01/25

Peel Hunt Keeps Their Buy Rating on Oxford BioMedica (OXBDF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oxford BioMedica

3 Months

xxx

Success Rate

14/24 ratings generated profit

Average Return

+5.08%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +5.08% per trade.

1 Year

Charles WestonRBC Capital

Success Rate

11/24 ratings generated profit

Average Return

+11.80%

Copying Charles Weston's trades and holding each position for 1 Year would result in 45.83% of your transactions generating a profit, with an average return of +11.80% per trade.

2 Years

xxx

Success Rate

9/24 ratings generated profit

Average Return

+7.10%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of +7.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OXB Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OXB has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. OXB average Analyst price target in the past 3 months is 920.50.

Each month's total comprises the sum of three months' worth of ratings.

OXB Financial Forecast

OXB Earnings Forecast

Next quarter’s earnings estimate for OXB is -0.08 p with a range of -0.10 p to -0.05 p. The previous quarter’s EPS was -0.25 p. OXB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year OXB has Performed in-line its overall industry.

OXB Sales Forecast

Next quarter’s sales forecast for OXB is 93.35M with a range of 92.20M to 94.50M . The previous quarter’s sales results were 73.22M . OXB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year OXB has Performed in-line its overall industry.

OXB Stock Forecast FAQ

What is GB:OXB’s average 12-month price target, according to analysts?

Based on analyst ratings, Oxford BioMedica plc’s 12-month average price target is 920.50.

What is GB:OXB’s upside potential, based on the analysts’ average price target?

Oxford BioMedica plc has 60.09% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Oxford BioMedica plc a Buy, Sell or Hold?

Oxford BioMedica plc has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Oxford BioMedica plc’s share price target?

The average share price target for Oxford BioMedica plc is 920.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 1,170.00 p ,and the lowest forecast is 735.00 p. The average share price target represents 60.09% Increase from the current price of 575 p.

What do analysts say about Oxford BioMedica plc?

Oxford BioMedica plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Oxford BioMedica plc?

To buy shares of GB:OXB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Oxford BioMedica (OXB) Share Forecast & Price Target

OXB Analyst Ratings

OXB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Oxford BioMedica

OXB Analyst Recommendation Trends

OXB Financial Forecast

OXB Earnings Forecast

OXB Sales Forecast

OXB Stock Forecast FAQ

Detailed List of Analyst Forecasts